Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ERYTHROPOIETIN for Off label use: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 43 adverse event reports in the FDA FAERS database where ERYTHROPOIETIN was used for Off label use.

Most Reported Side Effects for ERYTHROPOIETIN

Side Effect Reports % Deaths Hosp.
Product storage error 1,286 16.2% 1 20
Death 871 10.9% 854 62
Circumstance or information capable of leading to medication error 592 7.4% 0 3
Off label use 590 7.4% 66 130
Haemoglobin decreased 443 5.6% 18 143
Drug ineffective 370 4.7% 31 74
Anaemia 367 4.6% 36 157
Intercepted product administration error 301 3.8% 0 2
Incorrect product storage 268 3.4% 0 9
Fatigue 266 3.3% 21 62
Drug dose omission 240 3.0% 4 20
Hospitalisation 229 2.9% 24 211
Aplasia pure red cell 204 2.6% 9 66
Asthenia 173 2.2% 28 65
Dyspnoea 173 2.2% 22 67

Other Indications for ERYTHROPOIETIN

Product used for unknown indication (4,000) Anaemia (1,269) Nephrogenic anaemia (750) Chronic kidney disease (482) Myelodysplastic syndrome (215) Haemoglobin decreased (128) End stage renal disease (73) Anaemia of chronic disease (57) Renal failure (36) Hypertension (32)

Other Drugs Used for Off label use

LENALIDOMIDE (5,767) ECULIZUMAB (3,550) CERTOLIZUMAB PEGOL (2,256) ABOBOTULINUMTOXINA (2,170) LEVETIRACETAM (2,161) APREMILAST (1,995) PROPRANOLOL (1,576) CETIRIZINE (1,416) HUMAN IMMUNOGLOBULIN G (1,129) THALIDOMIDE (1,033)

Related Pages

ERYTHROPOIETIN Full Profile All Off label use Drugs ERYTHROPOIETIN Demographics ERYTHROPOIETIN Timeline